Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?

Noah FangDavid HaKimberly DongThomas LeungSydney LeeMarisa K Holubar Lina Meng

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

Keyphrases

clostridium difficile
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical practice
prognostic factors
emergency department
patient reported outcomes